← Back
Data updated: Mar 10, 2026
NATCO
OncologyInfectious DiseaseDermatology
NATCO is a generic drug manufacturer focused on Oncology, Infectious Disease, Dermatology. Key products include MOXIFLOXACIN HYDROCHLORIDE.
1986
Since
23
Drugs
-
Trials
259
Approved (2yr)
Recent Activity
TOPIRAMATE 2026-02-23
Labeling
TOPIRAMATE 2026-02-23
Labeling
TOPIRAMATE 2026-02-23
Labeling
TOPIRAMATE 2026-02-23
Labeling
TOPIRAMATE 2026-02-23
Labeling
TOPIRAMATE 2026-02-23
Labeling
TOPIRAMATE 2026-02-23
Labeling
TOPIRAMATE 2026-02-23
Labeling
IDELALISIB 2026-02-17
TELMISARTAN AND HYDROCHLOROTHIAZIDE 2026-02-17
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 32%
3 drugs Phase 2: 1
Infectious Disease 29%
3 drugs
Dermatology 19%
2 drugs
Gastroenterology 10%
1 drugs
Respiratory 10%
1 drugs
Pipeline Strength Pro
Loading...
Competitors Pro
Pfizer big-pharma
Oncology, Infectious Disease, Dermatology, Gastroenterology
APOTHECON specialty
Infectious Disease, Dermatology, Gastroenterology, Respiratory
Baxter specialty
Infectious Disease, Oncology, Dermatology
Gilead Sciences biotech
Infectious Disease, Oncology, Gastroenterology, Respiratory
EXTROVIS big-pharma
Oncology, Infectious Disease, Dermatology, Respiratory, Gastroenterology
Active (13)
Discontinued (10)
Company Info
- First Approval
- 1986-03-21
- Latest
- 2026-02-17
- Applications
- 24